Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria

References

• Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. N Engl J Med 2009;360: 439–43.
   PubMed Web of Science ®Google Scholar
• Cassell GH, Mekalanos J. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 2001;285: 601–5.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;25:633–4.
   Google Scholar
• Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, . Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 1969;166:122–3.
   PubMed Web of Science ®Google Scholar
• Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother 1994;34:853–8.
   PubMed Web of Science ®Google Scholar
• Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005;25:1353–64.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121–2.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 7^th ed. Approved standard M2-A7. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
   Google Scholar
• Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, Oliver A, .; Project ICARE. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE. J Clin Microbiol 2003;41:3142–6.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;3:159–66.
   Google Scholar
• Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069–77.
   PubMed Web of Science ®Google Scholar
• Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibrosis 2003;2:19–24.
   PubMedGoogle Scholar
• Lopez-Cerero L, de Cueto M, Diaz-Guerrero MA, Morillo C, Pascual A. Evaluation of the E-test method for fosfomycin susceptibility of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother 2007;59:810–2.
   PubMed Web of Science ®Google Scholar
• de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006;50:368–70.
   PubMed Web of Science ®Google Scholar
• Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997;40: 393–9.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619–29.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, . Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51: 1905–11.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Doi Y. A step closer to extreme drugs resistance (XDR) in Gram negative bacilli. Clin Infect Dis 2007;45: 1179–81.
   PubMed Web of Science ®Google Scholar
• Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(Suppl 2):43–8.
   Google Scholar
• Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111–20.
   PubMed Web of Science ®Google Scholar
• Faruqi S, McCreanor J, Moon T, Meigh R, Morice AH. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis. Int J Antimicrob Agents 2008;32:461–3.
   PubMed Web of Science ®Google Scholar
• Cree M, Stacey S, Graham N, Wainwright C. Fosfomycin—investigation of a possible new route of administration of an old drug. A case study. J Cyst Fibros 2007;6:244–6.
   PubMed Web of Science ®Google Scholar
• Guerin F, Henegar C, Spiridon G, Launay O, Salmon-Ceron D, Poyart C. Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-beta-lactamase gene from Saudi Arabia. J Antimicrob Chemother 2005;56: 601–2.
   PubMed Web of Science ®Google Scholar
• Waiwarawooth J. Combination treatment of piperacillin/ tazobactam, amikacin and fosfomycin for probable multidrug-resistant Pseudomonas aeruginosa infection: a case report. J Infect Dis Antimicrob Agents 2004;21:89–91.
   Google Scholar
• Katznelson D, Yahav Y, Rubinstein E. Fosfomycin in the treatment of cystic fibrosis. Eur J Clin Microbiol 1984;3:213.
   PubMedGoogle Scholar
• Xiong YQ, Potel G, Caillon J, Stephant G, Jehl F, Bugnon D, . Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:496–9.
   PubMed Web of Science ®Google Scholar
• Kumon H, Ono N, Iida M, Nickel JC. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 1995;39:1038–44.
   PubMed Web of Science ®Google Scholar
• Mikuniya T, Kato Y, Kariyama R, Monden K, Hikida M, Kumon H. Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm. Acta Med Okayama 2005;59:209–16.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2009; Aug 20.
   Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND, Papafrangas EA. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008;27:439–43.
   PubMed Web of Science ®Google Scholar